FIGURE 2.

a, Twenty‐four‐week change in FDG SUVR in placebo‐ versus rasagiline‐treated patients. b, Longitudinal voxel‐based classifier results showing regions where rasagiline‐treated participants declined less in glucose metabolism than placebo‐treated participants